JP2016523863A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523863A5
JP2016523863A5 JP2016521853A JP2016521853A JP2016523863A5 JP 2016523863 A5 JP2016523863 A5 JP 2016523863A5 JP 2016521853 A JP2016521853 A JP 2016521853A JP 2016521853 A JP2016521853 A JP 2016521853A JP 2016523863 A5 JP2016523863 A5 JP 2016523863A5
Authority
JP
Japan
Prior art keywords
antigen
pharmaceutical composition
antibody
binding fragment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523863A (ja
JP6463351B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/043440 external-priority patent/WO2014205365A1/en
Publication of JP2016523863A publication Critical patent/JP2016523863A/ja
Publication of JP2016523863A5 publication Critical patent/JP2016523863A5/ja
Application granted granted Critical
Publication of JP6463351B2 publication Critical patent/JP6463351B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521853A 2013-06-21 2014-06-20 Il−4rアンタゴニストの投与により鼻茸を処置する方法 Active JP6463351B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361837912P 2013-06-21 2013-06-21
US61/837,912 2013-06-21
EP14305670.3 2014-05-07
EP14305670 2014-05-07
PCT/US2014/043440 WO2014205365A1 (en) 2013-06-21 2014-06-20 Methods for treating nasal polyposis by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018243929A Division JP6640977B2 (ja) 2013-06-21 2018-12-27 Il−4rアンタゴニストの投与により鼻茸を処置する方法

Publications (3)

Publication Number Publication Date
JP2016523863A JP2016523863A (ja) 2016-08-12
JP2016523863A5 true JP2016523863A5 (enExample) 2017-06-29
JP6463351B2 JP6463351B2 (ja) 2019-01-30

Family

ID=50736018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521853A Active JP6463351B2 (ja) 2013-06-21 2014-06-20 Il−4rアンタゴニストの投与により鼻茸を処置する方法

Country Status (20)

Country Link
US (2) US10059771B2 (enExample)
EP (3) EP4663250A2 (enExample)
JP (1) JP6463351B2 (enExample)
KR (3) KR20160024916A (enExample)
CN (2) CN111437387B (enExample)
AU (4) AU2014284235C1 (enExample)
CA (1) CA2915839A1 (enExample)
CY (1) CY1122754T1 (enExample)
ES (1) ES3050809T3 (enExample)
HU (1) HUE073368T2 (enExample)
IL (1) IL243246B (enExample)
MX (1) MX368068B (enExample)
PL (2) PL3613432T3 (enExample)
PT (1) PT3613432T (enExample)
RS (1) RS59354B1 (enExample)
RU (1) RU2674680C2 (enExample)
SG (2) SG10201710557QA (enExample)
SI (1) SI3010539T1 (enExample)
TW (2) TWI709411B (enExample)
WO (1) WO2014205365A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
HRP20191709T1 (hr) * 2013-06-21 2019-12-13 Sanofi Biotechnology Postupci liječenja nosne polipoze davanjem antagonista il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
US10066017B2 (en) * 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
MA44238B1 (fr) 2016-02-19 2024-07-31 Regeneron Pharmaceuticals, Inc. Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
CN109789196B (zh) * 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
GB201802487D0 (en) * 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
EP3793597A1 (en) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
EP3878868B1 (en) * 2018-11-09 2024-10-09 Ajou University Industry-Academic Cooperation Foundation Human antibody having high affinity to human il-4 receptor alpha, and use thereof
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
CN113423435A (zh) 2018-12-28 2021-09-21 雷杰纳荣制药公司 使用花生四烯酸15-脂氧合酶(alox15)抑制剂治疗呼吸系统病症
SG11202109003QA (en) * 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Il-4rアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN114650828B (zh) 2019-09-20 2024-08-06 国立大学法人福井大学 药物组合物
EP4073810A1 (en) 2019-12-09 2022-10-19 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN117693362A (zh) * 2021-08-02 2024-03-12 甘李药业股份有限公司 含有抗il-4r抗体的稳定制剂
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
DE60130466T2 (de) 2000-07-26 2008-06-12 Hououdou Co. Ltd. Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7208579B2 (en) * 2003-05-30 2007-04-24 The Regents Of The University Of California IL4 receptor antagonists for horse, dog and cat
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
CA2554596A1 (en) 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypetides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
WO2008054606A2 (en) 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
RU2490278C2 (ru) * 2007-12-21 2013-08-20 Медиммун Лимитед ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
US20110008326A1 (en) * 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
EP2376656A4 (en) 2008-12-01 2012-05-16 Cincinnati Children S Hospital Medical Ct METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
RU2403071C1 (ru) * 2009-09-03 2010-11-10 Логина Наталия Алексеевна Способ лечения хронических рецидивирующих воспалительных заболеваний слизистой носа и околоносовых пазух методом эндоназальной аутолимфоцитотерапии
US20120240930A1 (en) * 2010-03-16 2012-09-27 Dan Allan Robert Kristensson Treatment of Asthma, Allergic Rhinitis and Improvement of Quality of Sleep by Temperature Controlled Laminar Airflow Treatment
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
RU2469737C1 (ru) * 2011-06-28 2012-12-20 Федеральное государственное учреждение "Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи" Министерства здравоохранения и социального развития России (СПб НИИ ЛОР МИНЗДРАВСОЦРАЗВИТИЯ РОССИИ) Способ лечения хронического риносинусита
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

Similar Documents

Publication Publication Date Title
JP2016523863A5 (enExample)
RU2016101632A (ru) Способы лечения полипоза носа путем введения антагониста il-4r
JP2017535547A5 (enExample)
JP2015527364A5 (enExample)
US20220204631A1 (en) Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
JP2017507139A5 (enExample)
KR102390714B1 (ko) 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
RU2015109716A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
JP2022160685A5 (enExample)
JP2021501169A5 (enExample)
JP2019529560A5 (enExample)
JP2017507945A5 (enExample)
JP2016534996A5 (enExample)
JP2020073525A5 (enExample)
JP2024016237A5 (enExample)
CA2917603A1 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
JP2025072440A5 (enExample)
JPWO2019222055A5 (enExample)
RU2015145135A (ru) Лечение воспалительных расстройств
JPWO2021026205A5 (enExample)
HRP20191709T1 (hr) Postupci liječenja nosne polipoze davanjem antagonista il-4r
JP2007506681A5 (enExample)
CN1646130A (zh) 类风湿性关节炎的治疗
JP2016502992A5 (enExample)
RU2023120407A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r